Medical Device Developments Weekly
Medical Device Developments
Latest news and insight on innovations in the Medical Device sector.
Welcome to this week's Medical Device Developments newsletter.
See the latest insight and analysis from the global medical device market from the last week below:
Wellvii Inc and B-Secur partner on BP and heart health monitoring device
Wellvii has developed the BP Go Rhythm device that records blood pressure from the finger. The US Food and Drug Administration (FDA)-cleared product is designed to replace the traditional NIBP arm cuff.
According to Wellvii, the device will increase convenience, comfort, and portability than existing devices. It will also transform ambulatory, remote patient monitoring, and home monitoring.
OrthAlign, Inc. secures FDA 510(k) approval for Lantern Hip navigation system
Lantern Hip technology is designed to support direct anterior total hip arthroplasty with the patient in the supine position.
It is the latest addition to the Lantern platform, which comprises other applications for total knee, revision knee, and partial knee arthroplasty.
BioIntelliSense, Inc secures FDA approval for BioButton and BioDashboard
BioButton is a rechargeable and reusable inpatient solution, which is said to expand the company’s continuous patient monitoring solutions portfolio.
It enables automating vital sign collection across medical-surgical units, speciality care areas, and emergency departments and delivers hospital-level care at home.
Study demonstrates superiority of Kerecis fish-skin for diabetic foot ulcer treatment
The study is by far the largest randomized controlled trial (RCT) of its kind because of the number of patients and severity of the wounds studied (University of Texas grades 2 and 3).
The findings underscore the efficacy of fish-skin grafts in the treatment of diabetic foot ulcers (DFU), offering new hope and improved outcomes for patients.
领英推荐
Medinol completes first-in-human use of ChampioNIR stent in Australia
The first-in-human implantations were carried out by surgeons Dr Gerard Goh and Dr Thodur Vasudevan of the Alfred Hospital in Melbourne Australia.
The ChampioNIR stent system combines a highly deliverable, and virtually un-fracturable stent that delivers the drug to every millimetre of the vessel surface.
FDA grants Breakthrough Device designation to Amphix Bio, Inc. Bio’s bone regeneration product
The designation covers the use of the therapeutic device to treat degenerative disc disease with transforaminal lumbar interbody fusion (TLIF) procedures.
The Breakthrough Devices Program is intended to accelerate the development, assessment, and review of new medical devices or drug-device combination products for more effective treatment of debilitating diseases or conditions.
Upcoming webinars
Recommended webinars
Thanks for reading; we hope you enjoyed it.
Until next week.
To have a story featured on next week's newsletter - contact Medical Device Developments or Jamie Mann directly.
#MedicalDeviceDevelopments